

# Cortider<sup>®</sup>

Hydrocortisone Acetate BP Cream

## DESCRIPTION

**Cortider<sup>®</sup>** cream is a preparation of Hydrocortisone Acetate. Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

## INDICATIONS

**Cortider<sup>®</sup>** cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

## DOSAGE & ADMINISTRATION

**Cortider<sup>®</sup>** cream is generally applied to the affected area as a thin film two or three times a day depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

## CONTRAINDICATIONS

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to Hydrocortisone.

## PRECAUTIONS

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions, which augment systemic absorption, include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests.

## **SIDE-EFFECTS**

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

## **USE IN PREGNANCY AND LACTATION**

Pregnancy Category C. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

## **PHARMACEUTICAL PRECAUTION**

Store in a dry place, away from light. Keep out of reach of children.

## **PACKAGING**

**Cortider®** Cream : Tube containing 10 g cream. Each gram cream contains Hydrocortisone Acetate BP 10 mg.

# **SK+F**

Manufactured by

**ESKAYEF BANGLADESH LIMITED**

MIRPUR, DHAKA, BANGLADESH

® REGD. TRADEMARK

M/PM00619 V02